Back to top
  • Open Daily at 10am
  • Call Ahead for Curbside Pickup
  • 443-438-3659

What Is CBDV (Cannabidivarin)?

Unraveling the Potential of CBDV (Cannabidivarin)

Curious about CBDV and its promising attributes? Let’s take a closer look at this cannabinoid that is making waves in the medical research community.

What is CBDV?

CBDV, or Cannabidivarin, is an exciting precursor to CBD. It is the result of a chemical reaction between CBGA and select enzymes. Acting as a molecule in waiting, CBDV has not yet undergone decarboxylation to convert into CBD, making it an intriguing subject for scientific exploration. Similar to CBD, CBDV does not induce a high, positioning it as a prime candidate for medical studies. Notably, CBDV is found in higher concentrations in specific subspecies of cannabis, particularly in landrace strains.

Potential Side Effects and Benefits

As of now, CBDV use in humans has not been associated with any adverse side effects. Some potential side effects may mirror those linked to CBD usage, such as dry mouth and low blood pressure. The non-psychotropic nature of CBDV makes it a compelling option for researchers looking into its medicinal properties.

Research Findings

While research on CBDV remains limited due to challenges in isolating this compound and navigating regulatory hurdles, some notable studies have shed light on its potential benefits. For instance, a study conducted by GW Pharmaceuticals in 2014 explored CBDV’s efficacy in treating epilepsy, indicating promising results. Additionally, CBDV has shown promise in easing symptoms of neurological disorders like Rett syndrome and Duchenne muscular dystrophy.

Legal Status

CBDV is not listed under the Convention on Psychotropic Substances, rendering it legally available for research purposes. However, its presence in specific cannabis strains, notably C. indica varieties, poses challenges in generating substantial quantities for study due to regulatory constraints.

As the scientific community continues to delve into the therapeutic potential of CBDV, more breakthroughs are on the horizon. With ongoing research studies and clinical trials, CBDV may emerge as a key component in the development of innovative treatment options for a variety of health conditions.

Sources

[1] Vigli, D., Cosentino, L., Raggi, C., Laviola, G., Woolley-Roberts, M., & de Filippis, B. (2018). Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology, 140, 121–129. [Source]

[2] Albert Einstein College of Medicine, INC, & Hollander, E. (2018, August). Cannabidivarin (CBDV) Versus Placebo in Children with Autism Spectrum Disorder (ASD) (No. W81XWH-17-1–0253). https://apps.dtic.mil/dtic/tr/fulltext/u2/1064689.pdf [Source]

[3] Rock, E. M., Sticht, M. A., Duncan, M., Stott, C., & Parker, L. A. (2013). Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9-tetrahydrocannabivarin (THCV), to produce CB1receptor inverse agonism symptoms of nausea in rats. British Journal of Pharmacology, 170(3), 671–678. [Source]

[4] Zamberletti, E., Gabaglio, M., Piscitelli, F., Brodie, J. S., Woolley-Roberts, M., Barbiero, I., Tramarin, M., Binelli, G., Landsberger, N., Kilstrup-Nielsen, C., Rubino, T., di Marzo, V., & Parolaro, D. (2019). Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. Journal of Psychopharmacology, 33(7), 894–907. [Source]

[5] Vigli, D., Cosentino, L., Raggi, C., Laviola, G., Woolley-Roberts, M., & de Filippis, B. (2018). Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology, 140, 121–129. [Source]